Serum Albumin and Its Trajectory Are Associated With Therapeutic Outcomes in Ulcerative Colitis
- 16 December 2024
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (10) , 1808-1816
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Medical Science and Technology Foundation of Guangdong Province
This publication has 29 references indexed in Scilit:
- Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIBScientific Reports, 2024
- Ulcerative colitisThe Lancet, 2023
- Inflammation and malnutrition in inflammatory bowel diseaseThe Lancet Gastroenterology & Hepatology, 2023
- Albumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeuticsJournal of Controlled Release, 2022
- Predictors of Placebo Induction Response and Remission in Ulcerative ColitisClinical Gastroenterology and Hepatology, 2022
- Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2021
- Can molecular stratification improve the treatment of inflammatory bowel disease?Pharmacological Research, 2019
- Serum albumin and health in older people: Review and meta analysisMaturitas, 2015
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007